The DEA Plans to Ban Opioid-Like Kratom Compound 7-OH
Overview
The federal agency says it will temporarily schedule the drug, which has been called "gas station heroin," as a controlled substance—a move welcomed by the MAHA (Make America Healthy Again) movement and by much of the mainstream kratom industry. The action targets a specific compound, not the plant itself, and reflects growing concern over how kratom-derived products are being sold and marketed in convenience stores and smoke shops. Visit robosino.com
What Is 7-OH and Why It's Controversial
Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia, and contains dozens of naturally occurring alkaloids. 7-hydroxymitragynine (7-OH) is one of these alkaloids, but it typically exists in raw kratom leaf only in trace amounts. The products drawing regulatory scrutiny are not traditional leaf kratom but concentrated or synthesized extracts engineered to boost 7-OH content far beyond what occurs naturally. Because 7-OH binds to opioid receptors more potently than the plant's dominant alkaloid, mitragynine, critics argue these concentrated products function more like an unregulated opioid than a botanical supplement—hence the "gas station heroin" label.
The DEA's Proposed Scheduling Action
By moving to temporarily schedule 7-OH as a controlled substance, the DEA is using an emergency mechanism that allows federal authorities to restrict a substance while a fuller review is conducted, rather than going through the full multi-year scheduling process. This is not the agency's first attempt to regulate kratom-related compounds: a 2016 effort to place the entire kratom plant into Schedule I was withdrawn after a wave of public and congressional pushback from kratom users and advocacy groups. The current action is narrower, focusing specifically on isolated or concentrated 7-OH rather than the whole leaf or low-dose traditional kratom products.
Industry and MAHA Reaction
The scheduling plan has drawn support from parts of the kratom industry itself, including groups that have long pushed for a legal distinction between traditional leaf-based kratom and high-potency 7-OH extracts sold as pills, shots, or gummies. These industry voices argue that unregulated 7-OH products damage the credibility of kratom broadly and expose consumers to unpredictable, opioid-like effects. The move also aligns with the broader MAHA agenda's focus on curbing substances seen as contributing to the opioid crisis, framing the ban as a public-health protection measure rather than an attack on kratom as a whole.
What This Means for Kratom Consumers
If finalized, the scheduling would make concentrated 7-OH products illegal to manufacture, distribute, or possess at the federal level, while traditional kratom leaf and powder—already legal in most states—would remain unaffected. Consumers and retailers should expect increased scrutiny of specialty kratom shots and extract products, particularly those marketed with vague or exaggerated potency claims. State-level kratom laws, which vary widely, will continue to govern the broader legality of leaf kratom regardless of the federal 7-OH action.
FAQ
Does this ban all kratom products? No. It targets concentrated 7-OH extracts specifically, not raw kratom leaf or powder.
Is kratom illegal now? Traditional kratom remains legal in most U.S. states; only the isolated 7-OH compound is subject to the DEA's scheduling action.
Why is 7-OH compared to heroin? Concentrated 7-OH binds opioid receptors more strongly than mitragynine, producing effects and risks regulators consider closer to opioids than to typical botanical supplements.
Source
Originally published at www.wired.com.